Notice2024-27096
Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Peptides and Peptide Microarrays for Detection and Differentiation of Antibody Responses to Ebola Virus and Other Pathogens.
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
November 20, 2024
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to The Trustees of Columbia University in the City of New York, Columbia Technology Ventures, located in New York, New York to practice the inventions embodied in the patent applications listed in the SUPPLEMENTARY INFORMATION section of this notice.
Full Text
<html>
<head>
<title>Federal Register, Volume 89 Issue 224 (Wednesday, November 20, 2024)</title>
</head>
<body><pre>
[Federal Register Volume 89, Number 224 (Wednesday, November 20, 2024)]
[Notices]
[Pages 91773-91774]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2024-27096]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License, Inter-Institutional
Agreement-Institution Lead: Peptides and Peptide Microarrays for
Detection and Differentiation of Antibody Responses to Ebola Virus and
Other Pathogens.
AGENCY: National Institutes of Health, National Institute of Allergy
and Infectious Diseases.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Allergy and Infectious Diseases, an
institute of the National Institutes of Health, Department of Health
and
[[Page 91774]]
Human Services, is contemplating the grant of an exclusive,
sublicensable patent license to The Trustees of Columbia University in
the City of New York, Columbia Technology Ventures, located in New
York, New York to practice the inventions embodied in the patent
applications listed in the SUPPLEMENTARY INFORMATION section of this
notice.
DATES: Only written comments and/or applications for a license which
are received by the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases on or
before December 5, 2024 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Wade Green, Ph.D., Lead Technology Transfer and
Patent Specialist, Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Suite 2G, MSC9804, Rockville, MD 20852-9804, phone number
301-761-7505, or <a href="/cdn-cgi/l/email-protection#f582949190db928790909bb59b9c9ddb929a83"><span class="__cf_email__" data-cfemail="4c3b2d2829622b3e2929220c222524622b233a">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: The following represents the intellectual
property to be licensed under the prospective agreement: U.S.
Provisional Patent Application Serial No. 68/428,826, filed November
30, 2022, titled ``Peptides And Peptide Microarrays For Detection And
Differentiation Of Antibody Responses To Ebola Virus And Other
Pathogens'' (HHS Reference No. E-028-2024-0-US-01) and International
Patent Application No. PCT/US23/81625, filed on November 29, 2023,
titled ``Peptides And Peptide Microarrays For Detection And
Differentiation Of Antibody Responses To Ebola Virus'' (HHS Reference
No. E-028-2024-0-PC-01). All rights in these inventions have been
assigned to The Trustees of Columbia University in the City of New
York, Columbia Technology Ventures and the Government of the United
States of America.
The prospective patent license will be for the purpose of
consolidating the patent rights with The Trustees of Columbia
University in the City of New York, Columbia Technology Ventures, the
co-owner of said rights, for commercial development and marketing.
Consolidation of these co-owned rights is intended to expedite
development of the invention, consistent with the goals of the Bayh-
Dole Act codified as 35 U.S.C. 200-212.
The prospective interinstitutional agreement will include an
exclusive license for NIAID's rights in these jointly owned patents. It
will be sublicensable, and any sublicenses granted by The Trustees of
Columbia University in the City of New York Columbia Technology
Ventures will be subject to the provisions of 37 CFR part 404.
The subject patent rights are related to novel peptides that enable
specific and sensitive serological detection of adaptive immune
responses to a wide range of clinically important high threat pathogens
circulating in sub-Saharan Africa on a wide range of platforms. These
assays allow identification of individuals who have been immunized and/
or infected with filoviruses.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and may be granted unless within fifteen (15) days from the date of
this published notice, the National Insitute of Allergy and Infectious
Diseases receives written evidence and argument that establishes that
the grant of the license would not be consistent with the requirements
of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: November 15, 2024.
Jeremiah D. Mitzelfelt,
Acting Deputy Director, Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-27096 Filed 11-19-24; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on November 20, 2024.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.